Long-Acting Cabotegravir and Rilpivirine in Patients With HIV With Solid Organ Transplantation: A Case Series
Open Forum Infectious Diseases · 31.07.2025 · 12 (8)
DOI: 10.1093/ofid/ofaf470 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 18.08.2025. Verfasst von Ana Moreno und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, University Hospital Ramón y Cajal, IRYCIS, Madrid, Spain. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Managing individuals with both HIV infection and a history of solid organ transplantation presents unique challenges due to interactions between antiretroviral therapy and immunosuppressive regimens. Long-acting injectable therapies may offer advantages in reducing drug interactions and improving adherence.
Methods
This retrospective study assessed the virological efficacy and safety of long-acting injectable therapy with a combination of 2 antiviral agents in 5 patients with stable HIV infection who had undergone kidney or liver transplantation. Patients were followed for up to 74 weeks after initiating therapy. Virological response, immunological parameters, renal and hepatic function, and immunosuppressive drug levels were monitored.
Results
All patients maintained undetectable viral loads throughout the study period, with no virological failure or drug-resistance development. CD4+ T-cell counts remained stable, and no clinically significant changes in renal or hepatic function were observed. Immunosuppressive drug levels remained within the therapeutic range without requiring dose adjustments. No patient experienced severe adverse effects or injection-site complications, and adherence was high throughout the study.
Conclusions
Long-acting injectable therapy was effective and well tolerated in individuals with stable HIV infection following solid organ transplantation. The findings suggest that this approach may be a viable treatment option, reducing drug interactions while maintaining virological suppression. Further research with larger cohorts is needed to confirm these findings and establish guidelines for implementation in transplant recipients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infectious Diseases, University Hospital Ramón y Cajal, IRYCIS, Madrid, Spain.
- CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
- Gastroenterology Department (Liver Transplant Unit), University Hospital Ramon y Cajal, Madrid, Spain.
- Pharmacy Department, University Hospital Ramon y Cajal, Madrid, Spain.
ORCID-Profile: Ana Moreno, Ruben Fernandez-Ibanez, Jose L Casado, Maria J Vivancos, Santiago Moreno
Zitieren
APA
Moreno, A., Fernandez-Ibanez, R., Del Campo, S., Perez-Elias, M. J., Casado, J. L., Garcia, M., Velez, M., Vivancos, M. J., & Moreno, S. (2025). Long-Acting Cabotegravir and Rilpivirine in Patients With HIV With Solid Organ Transplantation: A Case Series. Open Forum Infectious Diseases, 12(8). https://doi.org/10.1093/ofid/ofaf470
Vancouver
Moreno A, Fernandez-Ibanez R, Del Campo S, Perez-Elias MJ, Casado JL, Garcia M, et al. Long-Acting Cabotegravir and Rilpivirine in Patients With HIV With Solid Organ Transplantation: A Case Series. Open Forum Infectious Diseases. 2025;12(8). doi:10.1093/ofid/ofaf470
BibTeX
@article{Moreno2025,
author = {Moreno, Ana and Fernandez-Ibanez, Ruben and Del Campo, Santos and Perez-Elias, Maria J and Casado, Jose L and Garcia, Miguel and Velez, Manuel and Vivancos, Maria J and Moreno, Santiago},
title = {Long-Acting Cabotegravir and Rilpivirine in Patients With HIV With Solid Organ Transplantation: A Case Series},
journal = {Open Forum Infectious Diseases},
year = {2025},
volume = {12},
number = {8},
doi = {10.1093/ofid/ofaf470}
}
EUVIMED